Perrigo Company plc Research and Development Expense
Perrigo Company plc (PRGO) reported Research and Development Expense of $23.70 million for the 3-month period ending 2026-06-27, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-05
- Perrigo Company plc research and development expense for the quarter ending 2026-06-27 was $23.70M, a 7.73% increase year-over-year.
- Perrigo Company plc research and development expense for the quarter ending 2026-03-28 was $24.60M, a 7.87% decline year-over-year.
- Perrigo Company plc research and development expense for the quarter ending 2025-12-31 was $21.80M, a 21.58% decline year-over-year.
- Perrigo Company plc research and development expense for the quarter ending 2025-09-27 was $24.90M, a 4.23% decline year-over-year.
- Perrigo Company plc research and development expense for fiscal 2025 was $95.40M, a 14.97% decline from fiscal 2024.
- Perrigo Company plc research and development expense for fiscal 2024 was $112.20M, a 8.41% decline from fiscal 2023.
- Perrigo Company plc research and development expense for fiscal 2023 was $122.50M, a 0.49% decline from fiscal 2022.
- Perrigo Company plc research and development expense for fiscal 2022 was $123.10M, a 0.90% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-27 | $23.70M 10-Q · filed 2026-08-05 | $48.40M 10-Q · filed 2026-08-05 | $70.10M derived: sum of 3 quarters · filed 2026-08-05 | $95.00M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2026-03-28 | $24.60M 10-Q · filed 2026-05-06 | $46.40M derived: sum of 2 quarters · filed 2026-05-06 | $71.30M derived: sum of 3 quarters · filed 2026-05-06 | $93.30M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-12-31 | $21.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $46.70M derived: sum of 2 quarters · filed 2026-02-26 | $68.70M derived: sum of 3 quarters · filed 2026-08-05 | $95.40M 10-K · filed 2026-02-26 | ||||
| 2025-09-27 | $24.90M 10-Q · filed 2025-11-05 | $46.90M derived: sum of 2 quarters · filed 2026-08-05 | $73.60M 10-Q · filed 2025-11-05 | $101.40M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-06-28 | $22.00M 10-Q · filed 2026-08-05 | $48.70M 10-Q · filed 2026-08-05 | $76.50M derived: sum of 3 quarters · filed 2026-08-05 | $102.50M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-03-29 | $26.70M 10-Q · filed 2026-05-06 | $54.50M derived: sum of 2 quarters · filed 2026-05-06 | $80.50M derived: sum of 3 quarters · filed 2026-05-06 | $109.90M derived: sum of 4 quarters · filed 2026-05-06 | ||||
| 2024-12-31 | $27.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $53.80M derived: sum of 2 quarters · filed 2026-02-26 | $83.20M derived: sum of 3 quarters · filed 2026-02-26 | $112.20M 10-K · filed 2026-02-26 | ||||
| 2024-09-28 | $26.00M 10-Q · filed 2025-11-05 | $55.40M derived: sum of 2 quarters · filed 2025-11-05 | $84.40M 10-Q · filed 2025-11-05 | $114.00M derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2024-06-29 | $29.40M 10-Q · filed 2025-08-06 | $58.40M 10-Q · filed 2025-08-06 | $88.00M derived: sum of 3 quarters · filed 2026-02-26 | $117.60M derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2024-03-30 | $29.00M 10-Q · filed 2025-05-07 | $58.60M derived: sum of 2 quarters · filed 2026-02-26 | $88.20M derived: sum of 3 quarters · filed 2026-02-26 | $120.40M derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2023-12-31 | $29.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $59.20M derived: sum of 2 quarters · filed 2026-02-26 | $91.40M derived: sum of 3 quarters · filed 2026-02-26 | $122.50M 10-K · filed 2026-02-26 | ||||
| 2023-09-30 | $29.60M 10-Q · filed 2024-11-06 | $61.80M derived: sum of 2 quarters · filed 2024-11-06 | $92.90M 10-Q · filed 2024-11-06 | $125.50M derived: sum of 4 quarters · filed 2025-02-28 | ||||
| 2023-07-01 | $32.20M 10-Q · filed 2024-08-02 | $63.30M 10-Q · filed 2024-08-02 | $95.90M derived: sum of 3 quarters · filed 2025-02-28 | $125.70M derived: sum of 4 quarters · filed 2025-02-28 | ||||
| 2023-04-01 | $31.10M 10-Q · filed 2024-05-07 | $63.70M derived: sum of 2 quarters · filed 2025-02-28 | $93.50M derived: sum of 3 quarters · filed 2025-02-28 | $125.00M derived: sum of 4 quarters · filed 2025-02-28 | ||||
| 2022-12-31 | $32.60M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $62.40M derived: sum of 2 quarters · filed 2025-02-28 | $93.90M derived: sum of 3 quarters · filed 2025-02-28 | $123.10M 10-K · filed 2025-02-28 | ||||
| 2022-10-01 | $29.80M 10-Q · filed 2023-11-07 | $61.30M derived: sum of 2 quarters · filed 2023-11-07 | $90.50M 10-Q · filed 2023-11-07 | $120.90M derived: sum of 4 quarters · filed 2024-02-27 | ||||
| 2022-07-02 | $31.50M 10-Q · filed 2023-08-08 | $60.80M 10-Q · filed 2023-08-08 | $91.10M derived: sum of 3 quarters · filed 2024-02-27 | $118.70M derived: sum of 4 quarters · filed 2024-02-27 | ||||
| 2022-04-02 | $29.30M 10-Q · filed 2023-05-09 | $59.60M derived: sum of 2 quarters · filed 2024-02-27 | $87.20M derived: sum of 3 quarters · filed 2024-02-27 | $120.20M derived: sum of 4 quarters · filed 2024-02-27 | ||||
| 2021-12-31 | $30.30M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $57.90M derived: sum of 2 quarters · filed 2024-02-27 | $90.90M derived: sum of 3 quarters · filed 2024-02-27 | $122.00M 10-K · filed 2024-02-27 | ||||
| 2021-10-02 | $27.60M 10-Q · filed 2022-11-08 | $60.60M derived: sum of 2 quarters · filed 2022-11-08 | $91.70M 10-Q · filed 2022-11-08 | $124.70M derived: sum of 4 quarters · filed 2023-02-28 | ||||
| 2021-07-03 | $33.00M 10-Q · filed 2022-08-09 | $64.10M 10-Q · filed 2022-08-09 | $97.10M derived: sum of 3 quarters · filed 2023-02-28 | $127.50M derived: sum of 4 quarters · filed 2023-02-28 | ||||
| 2021-04-03 | $31.10M 10-Q · filed 2022-05-11 | $64.10M derived: sum of 2 quarters · filed 2023-02-28 | $94.50M derived: sum of 3 quarters · filed 2023-02-28 | $124.90M derived: sum of 4 quarters · filed 2023-02-28 | ||||
| 2020-12-31 | $33.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $63.40M derived: sum of 2 quarters · filed 2023-02-28 | $93.80M derived: sum of 3 quarters · filed 2023-02-28 | $121.70M 10-K · filed 2023-02-28 | $177.70M 10-K · filed 2021-03-01 | |||
| 2020-09-26 | $30.40M 10-Q · filed 2021-11-12 | $42.60M 10-Q · filed 2020-11-05 | $60.80M derived: sum of 2 quarters · filed 2021-11-12 | $88.70M 10-Q · filed 2021-11-12 | $131.60M 10-Q · filed 2020-11-05 | $79.90M derived: sum of 4 quarters · filed 2022-03-01 | ||
| 2020-06-27 | $30.40M 10-Q · filed 2021-08-11 | $47.10M 10-Q · filed 2020-08-05 | $58.30M 10-Q · filed 2021-08-11 | $89.00M 10-Q · filed 2020-08-05 | $49.50M derived: sum of 3 quarters · filed 2022-03-01 | $93.50M derived: sum of 4 quarters · filed 2022-03-01 | ||
| 2020-03-28 | $27.90M 10-Q · filed 2021-05-12 | $41.90M 10-Q · filed 2020-05-05 | $19.10M derived: sum of 2 quarters · filed 2022-03-01 | $63.10M derived: sum of 3 quarters · filed 2022-03-01 | $107.00M derived: sum of 4 quarters · filed 2022-03-01 | |||
| 2019-12-31 | -$8.80M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $35.20M derived: sum of 2 quarters · filed 2022-03-01 | $79.10M derived: sum of 3 quarters · filed 2022-03-01 | $119.20M 10-K · filed 2022-03-01 | $187.40M 10-K · filed 2020-02-27 | |||
| 2019-09-28 | $44.00M 10-Q · filed 2020-11-05 | $87.90M derived: sum of 2 quarters · filed 2020-11-05 | $128.00M 10-Q · filed 2020-11-05 | $172.70M derived: sum of 4 quarters · filed 2021-03-01 | ||||
| 2019-06-29 | $43.90M 10-Q · filed 2020-08-05 | $84.00M 10-Q · filed 2020-08-05 | $128.70M derived: sum of 3 quarters · filed 2021-03-01 | $172.40M derived: sum of 4 quarters · filed 2021-03-01 | ||||
| 2019-03-30 | $40.20M 10-Q · filed 2020-05-05 | $84.80M derived: sum of 2 quarters · filed 2021-03-01 | $128.50M derived: sum of 3 quarters · filed 2021-03-01 | $220.40M derived: sum of 4 quarters · filed 2021-03-01 | ||||
| 2018-12-31 | $44.60M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $88.30M derived: sum of 2 quarters · filed 2021-03-01 | $180.20M derived: sum of 3 quarters · filed 2021-03-01 | $218.60M 10-K · filed 2021-03-01 | ||||
| 2018-09-29 | $43.70M 10-Q · filed 2019-11-06 | $135.60M derived: sum of 2 quarters · filed 2019-11-06 | $174.00M 10-Q · filed 2019-11-06 | $220.90M derived: sum of 4 quarters · filed 2020-02-27 | ||||
| 2018-06-30 | $91.90M 10-Q · filed 2019-08-08 | $130.30M 10-Q · filed 2019-08-08 | $177.20M derived: sum of 3 quarters · filed 2020-02-27 | $215.60M derived: sum of 4 quarters · filed 2020-02-27 | ||||
| 2018-03-31 | $38.40M 10-Q · filed 2019-05-09 | $85.30M derived: sum of 2 quarters · filed 2020-02-27 | $123.70M derived: sum of 3 quarters · filed 2020-02-27 | $166.30M derived: sum of 4 quarters · filed 2020-02-27 | ||||
| 2017-12-31 | $46.90M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $85.30M derived: sum of 2 quarters · filed 2020-02-27 | $127.90M derived: sum of 3 quarters · filed 2020-02-27 | $167.70M 10-K · filed 2020-02-27 | ||||
| 2017-09-30 | $38.40M 10-Q · filed 2018-11-08 | $81.00M derived: sum of 2 quarters · filed 2018-11-08 | $120.80M 10-Q · filed 2018-11-08 | $162.30M derived: sum of 4 quarters · filed 2019-02-27 | ||||
| 2017-07-01 | $42.60M 10-Q · filed 2018-08-09 | $82.30M 10-Q · filed 2018-08-09 | $123.90M derived: sum of 3 quarters · filed 2019-02-27 | $174.10M derived: sum of 4 quarters · filed 2019-02-27 | ||||
| 2017-04-01 | $39.80M 10-Q · filed 2018-05-08 | $81.30M derived: sum of 2 quarters · filed 2019-02-27 | $131.50M derived: sum of 3 quarters · filed 2019-02-27 | $178.50M derived: sum of 4 quarters · filed 2019-02-27 | ||||
| 2016-12-31 | $41.50M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | $91.70M derived: sum of 2 quarters · filed 2019-02-27 | $138.70M derived: sum of 3 quarters · filed 2019-02-27 | $184.00M 10-K · filed 2019-02-27 | ||||
| 2016-10-01 | $50.20M 10-Q · filed 2017-11-09 | $97.20M derived: sum of 2 quarters · filed 2017-11-09 | $142.50M 10-Q · filed 2017-11-09 | $189.10M derived: sum of 4 quarters · filed 2018-03-01 | ||||
| 2016-07-02 | $47.00M 10-Q · filed 2017-08-10 | $92.20M 10-Q · filed 2017-08-10 | $138.90M derived: sum of 3 quarters · filed 2018-03-01 | $180.50M derived: sum of 4 quarters · filed 2018-03-01 | ||||
| 2016-04-02 | $45.30M 10-Q · filed 2017-05-30 | $91.90M derived: sum of 2 quarters · filed 2018-03-01 | $133.50M derived: sum of 3 quarters · filed 2018-03-01 | $196.10M derived: sum of 4 quarters · filed 2018-03-01 | ||||
| 2015-12-31 | $46.60M derived: 10-K 6 month − 10-Q/A 3 month · filed 2018-03-01 | $88.20M 10-K · filed 2018-03-01 | $150.80M derived: sum of 3 quarters · filed 2018-03-01 | $186.20M derived: sum of 4 quarters · filed 2018-03-01 | ||||
| 2015-09-26 | $41.60M 10-Q/A · filed 2017-05-23 | $104.20M derived: sum of 2 quarters · filed 2017-05-23 | $139.70M 10-Q/A · filed 2017-05-23 | $192.80M derived: sum of 4 quarters · filed 2017-05-23 | ||||
| 2015-06-27 | $62.60M 10-Q/A · filed 2017-05-22 | $98.00M 10-Q/A · filed 2017-05-22 | $151.20M derived: sum of 3 quarters · filed 2017-05-22 | $187.80M 10-K · filed 2018-03-01 | ||||
| 2015-03-28 | $35.40M 10-Q/A · filed 2017-05-22 | $88.60M derived: sum of 2 quarters · filed 2017-05-22 | $125.20M 10-Q · filed 2015-04-29 | $163.20M derived: sum of 4 quarters · filed 2017-05-22 | ||||
| 2014-12-27 | $53.20M 10-Q · filed 2015-02-05 | $89.80M 10-K · filed 2018-03-01 | $127.80M derived: sum of 3 quarters · filed 2017-05-22 | $172.50M derived: sum of 4 quarters · filed 2017-05-22 | ||||
| 2014-09-27 | $36.60M 10-Q · filed 2015-11-02 | $74.60M derived: sum of 2 quarters · filed 2017-05-22 | $119.30M derived: sum of 3 quarters · filed 2017-05-22 | $156.80M derived: sum of 4 quarters · filed 2017-05-22 | ||||
| 2014-06-28 | $38.00M derived: 10-K 12 month − 10-Q 9 month · filed 2017-05-22 | $82.70M derived: sum of 2 quarters · filed 2017-05-22 | $120.20M derived: sum of 3 quarters · filed 2017-05-22 | $152.50M 10-K · filed 2017-05-22 | ||||
| 2014-03-29 | $44.70M 10-Q · filed 2015-04-29 | $82.20M derived: sum of 2 quarters · filed 2015-04-29 | $114.50M 10-Q · filed 2015-04-29 | $145.50M derived: sum of 4 quarters · filed 2016-02-25 | ||||
| 2013-12-28 | $37.50M 10-Q · filed 2015-02-05 | $69.80M 10-Q · filed 2015-02-05 | $100.80M derived: sum of 3 quarters · filed 2016-02-25 | $129.30M derived: sum of 4 quarters · filed 2016-02-25 | ||||
| 2013-09-28 | $32.30M 8-K · filed 2014-11-20 | $63.30M derived: sum of 2 quarters · filed 2016-02-25 | $91.80M derived: sum of 3 quarters · filed 2016-02-25 | $120.10M derived: sum of 4 quarters · filed 2016-02-25 | ||||
| 2013-06-29 | $31.00M derived: 10-KT 12 month − 10-Q 9 month · filed 2016-02-25 | $59.50M derived: sum of 2 quarters · filed 2016-02-25 | $87.80M derived: sum of 3 quarters · filed 2016-02-25 | $115.20M 10-KT · filed 2016-02-25 | ||||
| 2013-03-30 | $28.50M 10-Q · filed 2014-05-07 | $56.80M derived: sum of 2 quarters · filed 2014-05-07 | $84.20M 10-Q · filed 2014-05-07 | |||||
| 2012-12-29 | $28.30M 10-Q · filed 2014-02-06 | $55.70M 10-Q · filed 2014-02-06 | ||||||
| 2012-06-30 | $105.80M 10-K · filed 2014-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |